Hematological Malignancies

Duration of Response in 90 Y Ibritumomab Tiuxetan Trials Phase I-II Phase II

Phase III

n = 51

n = 30

n = 73

Overall Response, % Median DR, months

73

83

80

11.7

11.5

13.9

CR/CRu, %

29* 28*

47 23

34 23

Median DR, months

Ongoing CR/CRu, %

19

14

32

Median DR, months

62.1

41.2

42.2

Range

60+ to 66+

40+ to 42+

33+ to 48+

*Patients with CR only.

Gordon et al. Blood 2004.